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Indications to respiratory syncytial virus
immunoprophylaxis in the 29–32 wGA
group: is there still room for debating?
Gianvincenzo Zuccotti and Valentina Fabiano*
Abstract
Guidelines on immunoprophylaxis for prevention of RSV infection recommend it in preterm babies born before 29
wGA; in babies affected by bronchopulmonary dysplasia or congenital heart defects; and in post-heart transplantation
patients. On the contrary, immunoprophylaxis is not recommended in preterm babies born between 29 and 35 wGA.
We evaluated the impact of RSV-related healthcare expenditures in infants in the first 3 years of life in Italy, Lombardy
Region. In light of the collected data and considering the cost of a complete palivizumab prophylaxis, extending it to
babies 29–32 wGA, aged less than 6 months, appears to be a cost-effective strategy.
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Dear editor
It is well known that community-acquired respiratory
syncytial virus (RSV) infection represents a significant
healthcare issue in infants in the very first months of life,
and in particular in those born prematurely.
A recent US observational cohort study [1] demon-
strated that preterm infants born 29 to 35 weeks gesta-
tional age (wGA) not receiving immunoprophylaxis with
palivizumab are at high risk for severe RSV disease, par-
ticularly in the first months of life. RSV disease repre-
sents also a risk factor for development of wheezing and
asthma, reduced lung function, and irreversible airway
obstruction [2]. Moreover, hospitalizations, Emergency
Room and outpatient visits for community-acquired
RSV disease are associated with significant resources
consumption and increased healthcare costs, as demon-
strated by a recently published Italian study [3].
Current Italian Guidelines recommend with a Level of
Evidence II and Strength of recommendation A that: for
infants of 29–35 weeks gestational age and age
≤6 months at the beginning of the epidemic season,
prophylaxis with palivizumab might be taken into con-
sideration in presence of risk conditions predisposing to
severe infections and/or need for hospitalization [4, 5].
On the contrary, the recent recommendations of the
American Academy of Pediatrics, removed otherwise
healthy preterm infants born > 29 weeks of gestation
from the high-risk groups recommended to receive
palivizumab prophylaxis. Consequently, the Italian Drug
Agency (AIFA) most recently decided the total financial
coverage by the National Health Service of the palivizu-
mab prescription to the healthy preterms only for the
<29 wGA group and age ≤12 months.
We evaluated the total number of hospitalizations and
Emergency Room and/or outpatient visits in infants in
the first 3 years of life in Italy, Lombardy Region, and
the related total expenditures by the Regional Healthcare
System. We considered 65.496 babies born alive in 2013,
classified by sex and by GA in four groups: 24–28 wGA,
29–32 wGA, 33–34 wGA, ≥ 35 wGA (Table 1). For all
groups, the total number of hospitalizations in the
period 2013–2015 was 22.974. 680 babies in the 29–32
wGA group needed 731 hospitalizations and 600 babies
in the same group needed 11.603 Emergency Room and/
or outpatients visits; with a total expenditure of
2.121.775 € (median expenditure per patient: 3120 €) for
hospitalizations, and of 583.996 € for other healthcare
facilities use. We analyzed the hospitalizations according
to the International Classification of Diseases 9th Revi-
sion (ICD-9), considering the codes 079.6, corresponding
to RSV infection; 446.x corresponding to acute
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bronchitis, acute bronchitis caused by RSV, acute bron-
chiolitis caused by viruses other than RSV; 485 pneumo-
nia; and 486 corresponding to pneumonia caused by
unspecified agents. 16.8% (3616) of hospitalizations was
performed because of diseases included in one of these
ICD-9 codes; most frequent diagnoses were those in-
cluded in the 466.x ICD-9 code, reported in 2764
(12.9%) hospitalizations. According to GA, 93 babies of
the 29–32 wGA group were hospitalized for one of these
diagnoses, and 73 of these for acute bronchitis, acute
bronchitis caused by SRV, acute bronchiolitis caused by
viruses other than RSV (ICD-9 code 466.x).
The cost of a complete palivizumab prophylaxis (5
doses) is 4071 € per patient. If we had performed
palivizumab immunoprophylaxis in the 680 babies
29–32 wGA who were hospitalized, total expenditure
would have been 2,8 million €. The total cost of the
93 hospitalizations in the 29–32 wGA group for three
years was 1,6 million €, and the cost of other health-
care facilities consumption was 0,6 million €, giving a
total expenditure of 2,2 million €.
If we consider to administer palivizumab prophylaxis
in babies 29–32 wGA and aged less than 6 months
(presumably 70% of them), we may estimate a total
expenditure of 1,9 million €, saving more or less 0,3
million €. In addition, if we consider also the disease im-
pact on chronic respiratory sequelae and the many other
disease-related indirect costs, we may suppose that
healthcare costs saving would be even greater.
In light of these data, extending palivizumab prophy-
laxis to babies 29–32 wGA, aged less than 6 months, ap-
pears to be a cost-effective strategy. Because of the
limitations of the study to a single Italian region, these
findings cannot be generalized, but strongly point to a
need to reevaluate the role of palivizumab prophylaxis in
the 29–32 wGA subpopulation. Debate on RSV prophy-
laxis is maybe not still definitely closed.
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Table 1 Distribution by sex and gestational age of babies born




n° % n° % n° %
24–28 124 0,4 101 0,3 225 0,3
29–32 328 1,0 352 1,1 680 1,0
33–34 575 1,7 507 1,6 1.082 1,7
> = 35 32.681 96,9 30.828 97 63.509 97
Total 33.708 100 31.788 100 65.496 100
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